Monday, July 19, 2021 10:46:10 AM
The Company Has Launched a Search Process Subsequent to Former CEO and Director Robert Meister Stepping Down From His Roles
VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its Board of Directors (the “Board”) has appointed Adam Deffett as the Company’s Interim Chief Executive Officer (“CEO”) effective July 7, 2021. Mr. Deffett will continue to perform his duties as VP Capital Markets while holding the title of Interim CEO. Ketamine One’s former CEO, Robert Meister, has stepped down and also resigned from the Board to facilitate the Company’s pursuit of its new strategy subsequent to its previously announced name change. Ketamine One has launched on a search process to identify appropriate candidates and ultimately hire a permanent CEO to lead the Company, which it expects to complete in the coming months.
“I would like to thank Robert for stewarding the transition of the Company from an investment issuer under the name of Myconic Capital Corp. to a company dedicated to mental healthcare and the rebrand to Ketamine One,” said Adam Deffett, Interim CEO of Ketamine One. “I greatly appreciate the opportunity to lead Ketamine One during this exciting time as we execute on our vision of becoming a leader in mental health and wellness across North America. We are fortunate to have a leadership team with great depth, decades of operating experience and detailed knowledge of our businesses. Our team is working hard to establish Ketamine One as the preeminent mental health platform for patients, by aggregating existing medical clinics and establishing new locations, while supporting KGK Science as a leading clinical research organization and implementing leading technologies throughout the organization wherever possible,” added Mr. Deffett.
https://investorshub.advfn.com/secure/post_new.aspx?board_id=39822
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM